IQGAP1 and IGFBP2

• DOI: 10.1097/nen.0b013e31804567d7
• Publication Date: 2008-05-04T11:27:45Z
• Authors: Kerrie L. McDonald; Maree G. O'Sullivan; Jonathon F. Parki...; Janet M. Shaw; Cathy A. Payne; Janice M. Brewer; Lawrence Young; Dianne J. Reader; Helen T. Wheeler; Raymond J. Cook; Michael T. Biggs; Nicholas S. Little; Charlie Teo; Glenn Stone; Bruce G. Robinson
• Keywords: Grading (engineering); Immunostaining

Clinical treatment decisions and the survival outcomes of patients with gliomas are directly impacted by accurate tumor classification. New more reliable prognostic markers needed to better identify variable duration among histologically defined glioma grades. Microarray expression analysis immunohistochemistry were used biomarkers associated aggressive biologic behaviors. The protein IQGAP1 IGFBP2, when in conjunction World Health Organization grading system, readily identified a subgroup grade III whose prognosis was poor. In addition, glioblastoma multiforme, whom IGFBP2 absent, long-term than 3 years observed. use these confirmed nonuniform distribution those IV tumors. Thus, immunostaining supplements current histologic offering additional predictive information.